Stock Details
REGN is Regeneron Pharmaceuticals, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 635.32$. Average daily volumn in 3 months 683.05k. Market cap 75.09B

Stock symbol : REGN. Exchange : NasdaqGS. Currency : USD
Lastest price : 688.87$. Total volume : 800.89k. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Regeneron Pharmaceuticals, Inc. (REGN)
Last Price

Previous Close691.82
Day Range685.97-702.38
Bid687.49 x 800
Ask690.25 x 1.2k
Average Volume683.05k
Market Cap75.09B
52 Week Range538.01-754.67
Trailing P/E13.61
Foward P/E15.94
Dividend (Yield %)N/A
Ex-Dividend DateN/A

Financial Details

According to Regeneron Pharmaceuticals, Inc.'s financial reports the company's revenue in 2021 were 16.07B an decrease( +100%) over the years 2020 revenue that were of 8.5B. In 2021 the company's total earnings were 8.08B while total earnings in 2020 were 3.51B( +166.67%).

Loading ...


Market Cap:
Total Assets:
Total Cash:

News about "Regeneron Pharmaceuticals, Inc."


Allworth Financial LP Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : Defense World - 2 days ago

Allworth Financial LP grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN โ€“ Get Rating) by 95.7% during the second quarter, according to the company in its most recent ...See details»

Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO

Source from : Business Insider - 15 hours ago

PHOTON and PULSAR data presentations demonstrate aflibercept 8 mg led to sustained improvements in vision and anatomic measures of retinal fluid ...See details»

Regeneron Pharmaceuticals (NASDAQ: REGN)

Source from : The Motley Fool - 2 days ago

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.See details»


Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis

Source from : YAHOO!Finance - 1 days ago

The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, ...See details»


DAVENPORT & Co LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : Defense World - 3 days ago

DAVENPORT & Co LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN โ€“ Get Rating) by 0.6% during the second quarter, according to the company in its most recent Form 13F ...See details»


Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$16m worth of stock

Source from : YAHOO!Finance - 8 days ago

In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the ...See details»

REGN Regeneron Pharmaceuticals, Inc.

Source from : Seeking Alpha - 4 days ago

**NM signifies a non meaningful value. A dash signifies the data is not available.See details»

Regeneron : FDA Approves Dupixent For Prurigo Nodularis Treatment

Source from : Business Insider - 2 days ago

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, ...See details»

Sanofi, Regeneron Say Dupixent Gets FDA Approval to Treat Prurigo Nodularis Skin Disease

Source from : MarketWatch - 2 days ago

By Stephen Nakrosis Sanofi and Regeneron Pharmaceuticals Inc. said Wednesday the Food and Drug Administration approved Dupixent to treat patients ...See details»

Insiders who sold Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) earlier year may find some solace in the 4.1% drop

Source from : Yahoo! Sports - 3 days ago

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) stock price has dropped 4.1% in the previous week, but insiders who sold US$16m in stock over the past year have had less luck. Given that the ...See details»

Dupixentยฎ (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

Source from : Yahoo - 2 days ago

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixentยฎ (dupilumab) for the treatment of adult patients with ...See details»

Illumina aims to push genetics beyond the lab with $200 genome

Source from : The Spokesman-Review - 1 days ago

Illumina Inc. says it can read a person's entire genetic code for as little as $200 with its new sequencing machine, bringing the company within reach of its long-promised goal of the $100 genome.See details»


Biden Administration asks Supreme Court to reject Amgen's Repatha patent appeal

Source from : Reuters - 9 days ago

The Biden Administration told the U.S. Supreme Court on Wednesday that it should turn down a request by Amgen Inc to review a decision that invalidated patents on its blockbuster cholesterol drug ...See details»

Nasal Polyps Treatment Global Market Report 2022

Source from : - 21 hours ago announces the release of the report "Nasal Polyps Treatment Global Market Report 2022" - , Regeneron Pharmaceuticals Inc., Intersect ENT Inc., and AstraZeneca plc. The nasal polyps ...See details»